Fourth Quarter Highlights Full-Year Highlights Operational Highlights ® 2026 Full-Year Guidance CEO Commentary "Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America." - David Joyne ...

CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant's turnaround plan. "'24 was a tough year for the company. So '25 righted the ship," CVS CFO Brian Newman said in an interview. CVS, which operates one of the largest pharmacy chains in the U.S., sees full-year profit coming in between $7 to $7.20 per share. That's in line with the $7.17 per share that analy ...

Key TakeawaysThe U.S. House Judiciary Committee Republicans have issued subpoenas to eight major health insurers, including Elevance Health (ELV), CVS Health (CVS), Centene (CNC), Guidewell, and Oscar Health (OSCR), as part of an expanding investigation into potential fraud related to Affordable Care Act (ACA) premium subsidies.European officials are actively developing plans to gradually assume greater responsibility for the continent's defense, aiming to potentially replace U.S. strategic forces in Europe ...

Group 1 - The article provides a market analysis focusing on the S&P 500, State Street® Consumer Staples Select Sector SPDR® ETF, and iShares Expanded Tech-Software Sector ETF [1] - It highlights the performance trends and investment opportunities within these sectors [1] - The analysis is available on Investing.com, indicating a resource for investors seeking detailed insights [1]

Core Viewpoint - CVS Health is a significant player in the healthcare sector, with a diverse range of services and is set to release its quarterly earnings on February 10, 2026, with estimated EPS of $0.99 and revenue of approximately $103.57 billion [1][6] Financial Performance - CVS has consistently exceeded earnings estimates over the past four quarters, indicating strong financial performance [2] - For Q4 2025, analysts expect non-GAAP earnings of $0.99 per share, a decline from $1.19 per share in Q4 2024, potentially influenced by Medicare news [3] Market Valuation - CVS's P/E ratio of 212 suggests that investors are willing to pay a high price for its earnings, reflecting high expectations [3] - The price-to-sales ratio of 0.25 indicates that the market values CVS at 25 cents for every dollar of sales, while the enterprise value to sales ratio of 0.44 reflects its valuation in relation to sales [4] - The enterprise value to operating cash flow ratio of 18.89 highlights how the market values CVS's cash-generating ability [4] Capital Structure - CVS's debt-to-equity ratio of 1.12 shows a moderate use of debt in its capital structure [5] - The current ratio of 0.83 suggests potential liquidity concerns, as CVS has less than one dollar in current assets for every dollar of current liabilities [5] - The earnings yield of 0.47% provides a comprehensive view of CVS's financial health and market valuation [5]

Group 1 - The Federal Reserve's dual mandate will be addressed this week with the release of the January jobs report and the consumer price index [1] - Earnings reports from Cisco Systems, Applied Materials, and Arista are anticipated, which may provide insights into their financial performance and market conditions [1]

WOONSOCKET, R.I., Feb. 6, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that its approximately 9,000 community pharmacies are accepting TrumpRx discount cards, which offer savings on certain medications for those who are eligible, as determined by the drug manufacturers. ...

Core Viewpoint - CVS Health will replace Amgen and Eli Lilly's bone disease treatments with lower-cost alternatives in its preferred drug lists starting April 1 [1] Group 1 - CVS Health is making changes to its preferred drug lists to include more cost-effective options [1] - The decision reflects a broader trend in the healthcare industry towards reducing drug costs for consumers [1]

Shares of CVS Health (NYSE: CVS) have been declining recently as a potentially lower-than-expected increase in Medicare Advantage rates has investors worried about companies with exposure to health insurance. For CVS, health insurance is indeed a large part of its business as it owns Aetna, which serves millions of people throughout the country. Is CVS Health stock worth buying right now, on weakness, despite some concerning developments in the healthcare sector, or is it too risky to add it to your portfo ...

Core Viewpoint - CVS Health is enhancing access to lower-cost biosimilar medications, specifically osteoporosis treatments, by introducing new options in its formulary, which will be effective from April 1, 2026, providing significant cost savings compared to original brands [1]. Group 1: Introduction of Biosimilars - CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide options Bonsity and Tymlos, to its major national commercial template formularies [1]. - These biosimilars will replace Prolia and Forteo, offering customers more affordable alternatives with strong clinical and supply confidence [1]. Group 2: Cost Savings and Strategy - The preferred biosimilar approach is over 50% lower in costs per prescription compared to the original brand [1]. - CVS Caremark's biosimilar formulary strategy has already helped customers realize $1.5 billion in gross savings [5]. - The company has successfully transitioned 96% of its client members using Humira to a biosimilar, demonstrating its commitment to driving competition and cost savings [5]. Group 3: Specialty Drug Management - CVS Specialty proactively informs prescribers and patients about formulary changes, ensuring a smooth transition to covered alternatives [6]. - Advanced technology capabilities streamline the prescription process for doctors, allowing for quick approvals and enhancing patient communication [7]. Group 4: Importance of Biosimilars - Biosimilars are crucial for treating complex chronic conditions and are often injectable medications that require careful handling [8]. - The introduction of Ospomyv and Stoboclo is significant for treating osteoporosis, which is vital for preventing fractures and maintaining independence in older adults [9][10]. Group 5: Company Overview - CVS Health operates approximately 9,000 retail pharmacy locations and serves around 87 million plan members through its pharmacy benefits manager [11]. - The company aims to connect consumers to better health through personalized, technology-driven services, ultimately lowering overall healthcare costs [11].